

27th March 2026

Almirall together with CVS Caremark expand U.S. access for KLISYRI® (tirbanibulin) ointment for the treatment of actinic keratosis

- **Almirall announces expanded United States coverage for tirbanibulin following its addition to multiple CVS Caremark commercial formularies.**
- **The expanded coverage via CVS Caremark will broaden the potential access for U.S. patients to this innovative treatment.**
- **The announcement comes in the leadup to the American Academy of Dermatology (AAD) Annual Meeting in Denver, a leading international forum for medical dermatology expertise and collaboration.**

27th March 2026. Malvern, PA. Almirall S.A. (ALM), a global biopharmaceutical company dedicated to medical dermatology announces expanded U.S. patient access for tirbanibulin, which has been added to several CVS Caremark commercial formularies, including Standard Control, Advanced Control and Performance Standard.

This decision increases potential access for people commercially insured through CVS Caremark. This applies to those eligible for the treatment with KLISYRI covered under utilization management criteria that include one step-through of a prior topical field therapy and prior authorization to label. Almirall will continue to support patient access through the Almirall Advantage Program, which helps eligible commercially insured patients reduce out-of-pocket costs.

“As we come together at AAD to share new science and strengthen our commitment to dermatology, the expanded CVS Caremark coverage for tirbanibulin represents another important milestone for patients with actinic keratosis. By broadening access to innovative treatments for millions of people in the U.S., we are advancing our purpose to help people living with skin disease,” said **Paul Ritman, President & General Manager, Almirall U.S.**

CVS Caremark is one of the largest pharmacy benefit managers in the U.S, and the expansion means that 26 million commercially insured U.S. patients will now fall under formularies that include KLISYRI, giving more patients access to the treatment.

The news comes in the lead up to American Academy of Dermatology (AAD) Annual Meeting in Denver, a leading international forum for medical dermatology expertise and collaboration.

About KLISYRI (tirbanibulin) ointment, 1%:

INDICATION

KLISYRI is a microtubule inhibitor indicated for the topical field treatment of actinic keratosis on the face or scalp.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Ophthalmic Adverse Reactions

KLISYRI may cause eye irritation. Avoid transfer of the drug into the eyes and to the periocular area during and after application. Wash hands immediately after application. If accidental exposure occurs, instruct patient to flush eyes with water and seek medical care as soon as possible.

Local Skin Reactions

Local skin reactions, including severe reactions (erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration) in the treated area can occur after topical application of KLISYRI. Avoid use until skin is healed from any previous drug, procedure, or surgical treatment. Occlusion after topical application of KLISYRI is more likely to result in irritation.

ADVERSE REACTIONS

The most common adverse reactions (incidence $\geq 2\%$) were local skin reactions, application site pruritus, and application site pain.

Click here to view: [Prescribing information](#)

About Almirall

Almirall is a global biopharmaceutical company dedicated to medical dermatology. We closely collaborate with leading scientists, healthcare professionals, and patients to deliver our purpose: *to transform the patients' world by helping them realize their hopes and dreams for a healthy life*. We are at the forefront of science to deliver ground-breaking, differentiated medical dermatology innovations that address patients' needs.

Almirall, founded in 1944 and headquartered in Barcelona, is publicly traded on the Spanish Stock Exchange (ticker: ALM, total revenue in 2025: €1114.5 MM, over 2100 employees globally). Almirall products help to improve the lives of patients every day and are available in over 100 countries.

For more information, please visit <https://www.almirall.com/>

Corporate Communications

corporate.communication@almirall.com

Phone: (+34) 93 291 35 08

Investor Relations

investors@almirall.com

Phone: (+34) 93 291 30 87